Cargando...
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-label study evaluated the safety and antitu...
Gardado en:
| Publicado en: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer US
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6647393/ https://ncbi.nlm.nih.gov/pubmed/30993587 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00768-6 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|